Technical Analysis for MEIP - MEI Pharma, Inc.

Grade Last Price % Change Price Change
D 3.245 -3.99% -0.14
MEIP closed down 3.7 percent on Friday, April 16, 2021, on 54 percent of normal volume.
Earnings due: May 1
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical MEIP trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -3.99%
Bearish Engulfing Bearish -7.55%
20 DMA Support Bullish -7.55%
50 DMA Resistance Bearish -9.86%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -9.86%
Crossed Above 20 DMA Bullish -8.59%
MACD Bullish Signal Line Cross Bullish -8.59%
Inside Day Range Contraction -4.28%
Down 3 Days in a Row Weakness -2.26%
20 DMA Resistance Bearish -2.84%
Older End-of-Day Signals for MEIP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% 18 minutes ago
Down 3% 44 minutes ago
Down 2 % 44 minutes ago
Down 1% about 1 hour ago
Fell Below Previous Day's Low about 1 hour ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

MEI Pharma, Inc. Description

MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Clinical Medicine Clinical Development Solid Tumors Treatment Of Cancer Virotherapy Edwards Novogen Histone Deacetylase Inhibitor Refractory Solid Tumors

Is MEIP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.575
52 Week Low 2.28
Average Volume 981,934
200-Day Moving Average 3.14
50-Day Moving Average 3.70
20-Day Moving Average 3.48
10-Day Moving Average 3.47
Average True Range 0.23
ADX 12.04
+DI 19.69
-DI 19.43
Chandelier Exit (Long, 3 ATRs ) 3.15
Chandelier Exit (Short, 3 ATRs ) 3.87
Upper Bollinger Band 3.76
Lower Bollinger Band 3.20
Percent B (%b) 0.32
BandWidth 16.10
MACD Line -0.04
MACD Signal Line -0.05
MACD Histogram 0.0083
Fundamentals Value
Market Cap 380.32 Million
Num Shares 113 Million
EPS -0.75
Price-to-Earnings (P/E) Ratio -4.48
Price-to-Sales 9.21
Price-to-Book 3.92
PEG Ratio 20.60
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.68
Resistance 3 (R3) 3.70 3.62 3.63
Resistance 2 (R2) 3.62 3.54 3.61 3.61
Resistance 1 (R1) 3.50 3.50 3.46 3.48 3.60
Pivot Point 3.42 3.42 3.40 3.41 3.42
Support 1 (S1) 3.30 3.34 3.26 3.28 3.16
Support 2 (S2) 3.22 3.30 3.21 3.15
Support 3 (S3) 3.10 3.22 3.13
Support 4 (S4) 3.08